To the Newbies -- Esoteric is that interesting species of poster who loves to diss the stupid idiots on this board who are not as wealthy and skilled as he is. He thinks most people here are clueless and naïve. He’s a bit insufferable. For a taste of some of his “insight, ” his own words:
March 1 – “Most of us are not interested in hourly trading blips here. If you think we are going to sell this stock before the AD results shock the world just because the stock price might trade down a little temporarily, you are not too bright or you think Pran investors are not too bright.” (Whoops, Eso!!)
Feb 25—“As briane, or myself or others who have run divisions for major companies can tell you, Prana management already knows the AD trial is successful. Results may still be blinded, but they know.” (Double whoops!!!)
My advice -- he seems to be a financial whiz. Listen to them on such topics, but when he veers into evaluating the potential success of a developmental biotech, ignore him.
Many of you posters, blinded by your dislike of AF (who I think of as a fool), can't accept that the MD Anderson doctor is right. Well, he is. If you stepped back and asked yourself -- how do drug companies insure integrity in results? It is by having a third party run double-blind trials, and waiting for that third party to compile and release results when the third party deems such release to be appropriate. This is because premature disclosure of results in a trial can bias a trial in multiple ways. Furthermore, it can bias the market -- if a company cherry-picks data to release, and this affects the stock price, and then the trial has failed, you have misled investors. So it is ACCEPTED PROTOCOL not to release data in dribs and drabs during a study, except data related to safety. All that being said, the trial may well confirm NWBO's view, that DC-Vax is a winner.
Excellent, Pivalde. As I read this and other recent contributions to this board, I wonder if PBT2 will be an essential component of a multi-drug attack on Alzheimer's -- perhaps, like AIDS, this will require drug cocktails. Thoughts?
The dividend was not sustainable. It is now down to levels that should not be cut. The threat of a cut has been hanging over this stock, now it is done and over.
for some reason I can't copy and paste the text of the letter, but Prana Biotechnology replied on May 28th (Australian time) to the following ASX (Australian Stock Exchange) query: "is the company aware of any information concerning it that has not been announced to the market which, if known to some in the market, could explain the recent trading in its securities?" Geoffrey Kempler of Prana replied "No, the company is not aware of any information already released to the market. The company has not provided earnings guidance, and does not believe the share price is strongly related to the financial performance of the company at this stage." You can go to the ASX for the full letter. Just google ASX PBT and you will get to the relevant page with Prana info.
Nonsense. When I first started buying PRAN, it was in the 1.50 range. At that point, it had few results. The HD results alone mean that the value of the equity is greater than before. And, unlike some other biotechs, this one has an intriguing pipeline. One does not have to be a pumper to realize that this company has multiple possibilities. ll could fail, of course, but the HD results were decent enough to warrant further study. The AD results were a big disappointment but I don't think the last word is in on them . . .
Unlike you, who I have never before seen on this board, who is trying to force the price down for personal gain.
Nicely stated, rkf. There's plenty of room for a diversity of opinions. The best way to use this board is to listen to the science guys on the science, and ignore their advice on making money, and conversely, to pay close attention to the finance/ business whizzes on making money, but ignore them on anything having to do with science or the details of running trials. Following that approach, I'm up 200% on my PRAN investment so far, and holding the rest.
Um, what? He called Germany? you use that as an example of something to praise? He's a journalist -- or tries to APPEAR to be a journalist of sorts, so of course he will use a telephone. Praising him for picking up a telephone is a bit like praising me for putting on new clothes every morning.
Feurstein is so bad he doesn't even understand how to evaluate statistical significance of a trial. It's embarrassing. Praising him for taking photos, or having someone take photos, just doesn't cut the mustard.
The next time, Alwood, you decide to bleat
Remember this truth -- It's a tweet, not a tweat
Kadaicher, I am always a bit more cautious than you on potential. What you say is completely correct -- IF we see AD improvements etc., this will clearly result in multiples of the price. The reason I am cautiously optimistic is that Prana has multiple pathways to success. The macular degeneration patent is just the latest evidence in the potential power of MPACs.
I agree -- this is not like Incyte, where the president pulled down $1.7 million a year for several years before they launched their one and only cancer drug.
If you think Pivalde is a pumper, you need a check-up. Pivalde continually brings useful scientific references and abstracts to the board, and is an informed person on the science.